Recent Updates
Recently added Catalysts
LTRN Positive Sentiment

Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer

Wednesday, July 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Lantern Pharma has launched ZetaOmics, an autonomous computational biology module designed to enhance bioinformatics and multi-omic analysis for all cancer types. This innovative tool is particularly focused on addressing the needs of rare and pediatric cancers. The introduction of ZetaOmics marks a significant advancement in the company's AI-driven precision oncology efforts.
Price reaction · baseline $3.57 (2026-07-07 close) · hit pre-market · clean, no other LTRN news in the window
day 0 close · peak
-13.2%
day 1
-6.2%
day 3
-3.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of ZetaOmics enhances bioinformatics capabilities.
  • AI-driven platform targets rare and pediatric cancers.
  • Autonomous agent provides expert-grade analysis.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+272%
120-day peak, hindsight
Typical move
5.7%
average across 3 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
LP-300
Phase 2 · Adenocarcinoma of Lung

Full Press Release Details

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced the launch of ZetaOmics, the computational-biology module of its multi-agentic AI co-scientist platform, withZeta.ai. ZetaOmics introduces an autonomous “Computational Biologist” persona (agent) that performs real, end-to-end bioinformatics and multi-omic analysis — across any cancer type, and is purpose-built for the rare and pediatric cancers that have long been

Frequently Asked Questions

What is ZetaOmics?

ZetaOmics is an autonomous computational biology module launched by Lantern Pharma.

How does ZetaOmics assist in cancer research?

It performs end-to-end bioinformatics and multi-omic analysis across various cancer types.

What types of cancers does ZetaOmics focus on?

ZetaOmics is specifically designed for rare and pediatric cancers.

Who developed ZetaOmics?

ZetaOmics was developed by Lantern Pharma in collaboration with Zeta.ai.

ShareAdd on Google
Tags: LTRN Viatris Investor Conferences Healthcare Lantern Pharma ZetaOmics AI oncology cancer bioinformatics pediatric cancers
Last updated: Jul 8, 2026

Biotech snapshot

Cash runway
$7M liquidity · $1M/mo burn
~7 mo
Medium dilution risk
Lead asset
LP-300Phase 2
Adenocarcinoma of Lung →

Catalyst track record

+272%
best trade around LTRN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for LTRN.

See every catalyst's timing & PoA →